These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 7371772)

  • 1. Antibiotic resistome of Salmonella typhi: molecular determinants for the emergence of drug resistance.
    Kumar A; Kumar A
    Front Med; 2021 Oct; 15(5):693-703. PubMed ID: 34085183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.
    Huovinen P; Wolfson JS; Hooper DC
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):255-7. PubMed ID: 1597204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Jun; 23(6):405-30. PubMed ID: 7049657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of bacterial resistance--a challenge to the treatment of urinary infection.
    Slack R
    J Antimicrob Chemother; 1984 May; 13 Suppl B():1-7. PubMed ID: 6376460
    [No Abstract]   [Full Text] [Related]  

  • 5. Trimethoprim enhances the antibacterial activity of nalidixic and oxolinic acids and delays the emergence of resistance.
    Bertolini A; Castelli M; Genedani S; Garuti M
    Experientia; 1980 Feb; 36(2):243-4. PubMed ID: 7371772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of oxolinic acid and nalidixic acid against common urinary pathogens: a comparative study.
    de Rautlin de la Roy Y; Toma V; Bobin B
    Curr Med Res Opin; 1978; 5(9):743-8. PubMed ID: 738079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of flumequine against Escherichia coli: in vitro comparison with nalidixic and oxolinic acids.
    Greenwood D
    Antimicrob Agents Chemother; 1978 Mar; 13(3):479-83. PubMed ID: 400825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro action of oxolinic acid in comparison with nitrofurantoin and nalidixic acid].
    Grima P
    Minerva Urol; 1977; 29(5):225-7. PubMed ID: 611403
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparison of antibacterial activity of oxolinic acid (Gramurin) and nalidixic acid (Nevigramon) in vitro and in patients with urinary tract infections].
    Manitius A; Hebanowski M; Galiński J; Nowicki B
    Pol Tyg Lek; 1978 Aug; 33(34):1347-50. PubMed ID: 704439
    [No Abstract]   [Full Text] [Related]  

  • 10. Cross resistance of quinolone derivatives in gram-negative bacteria.
    Barba D; Pennucci C; Esposito S; Galante D
    Chemioterapia; 1985 Apr; 4(2):192-6. PubMed ID: 3159488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS.
    GOSS WA; DEITZ WH; COOK TM
    J Bacteriol; 1965 Apr; 89(4):1068-74. PubMed ID: 14276097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.
    GOSS WA; DEITZ WH; COOK TM
    J Bacteriol; 1964 Oct; 88(4):1112-8. PubMed ID: 14219026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREATMENT OF URINARY TRACT INFECTION WITH NALIDIXIC ACID.
    HOLLAND JT; MONTGOMERIE JZ
    N Z Med J; 1964 Aug; 63():498-501. PubMed ID: 14199476
    [No Abstract]   [Full Text] [Related]  

  • 14. ABSORPTION, EXCRETION, AND METABOLISM OF A NEW ANTIBACTERIAL AGENT, NALIDIXIC ACID.
    MCCHESNEY EW; FROELICH EJ; LESHER GY; CRAIN AV; ROSI D
    Toxicol Appl Pharmacol; 1964 May; 6():292-309. PubMed ID: 14194761
    [No Abstract]   [Full Text] [Related]  

  • 15. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.
    ELION GB; SINGER S; HITCHINGS GH
    J Biol Chem; 1954 Jun; 208(2):477-88. PubMed ID: 13174557
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.